News | Women's Health | July 08, 2015

Dutch Scientists Examining Breast MRI Screening for Women with Extremely Dense Breasts

VolparaDensity software helping randomize patients in study of detection efficacy

VolparaDensity, DENSE Trial, MRI, breast screening, mammography, Netherlands

July 8, 2015 - The first randomized trial investigating the additional value of magnetic resonance imaging (MRI) for screening women with dense breasts, is featured in the current issue of Radiology. The article, "MR Imaging as an Additional Screening Modality for the Detection of Breast Cancer in Women Aged 50–75 Years with Extremely Dense Breasts: The DENSE Trial Study Design," presents the rationale and design of the DENSE Trial. Run by Carla van Gils, M.D., and Wouter Veldhuis, M.D., from University Medical Center Utrecht (UMCU) in the Netherlands, the trial seeks to determine the effectiveness of screening with mammography and MRI compared to mammography alone in women who have extremely dense breasts.

Approximately 1 million women are screened every year in the Netherlands as part of the Dutch Breast Screening Program. To study the additional value of MRI, the DENSE Trial uses a randomized controlled design, with one group receiving mammography and the other group receiving mammography and MRI. VolparaDensity software from Volpara Solutions is being used in the trial to provide objective, volumetric breast density values. Participants with extremely dense breasts and a negative mammography result are randomized into two arms: one to have an additional MRI (n=7,237) and the other to follow the usual mammography screening program (n=28,948). The primary outcome is the difference in proportion of interval cancers between the arms. In order to be an effective screening strategy, the extra MRI screen-detected cancers have to be accompanied by a subsequent reduction in interval cancers.

Research has shown that mammography alone has significantly lower sensitivity in women with extremely dense breasts than in women with fatty breasts. With high sensitivity, even in the dense breast, MRI has the potential to improve cancer detection at an early stage; however, MRI is more costly and can increase the number of false-positives. The DENSE Trial aims to validate personalization of the national breast cancer screening program by incorporating information on mammographic density.

"Automated, objective density assessment was critical for this project, which is why we selected Volpara. The software's robust nature and clinical track record was once again validated by the results of the ASSURE project we recently presented at ECR, which demonstrated the direct correlation of mammographic screening performance to each patient's breast density categorization as determined by VolparaDensity," stated van Gils.

"The major strength of the DENSE Trial is its parallel-group randomized controlled design. As far as we are aware, DENSE is the first randomized trial investigating the additional value of MRI in women with extremely dense breasts" she added.

VolparaDensity is in use at breast imaging centers worldwide to help radiologists objectively assess density from both digital mammography and tomosynthesis images, and to determine which women would benefit from additional screening. Highly correlated to breast MR assessments, VolparaDensity automatically generates an objective measurement of volumetric breast density correlated to the American College of Radiology (ACR) breast density categories. To date, more than 5 million women have had their breast density analyzed using VolparaDensity.

For more information:

Related Content

Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Machine Learning Uncovers New Insights Into Human Brain Through fMRI
News | Neuro Imaging | January 11, 2019
An interdisciplinary research team led by scientists from the National University of Singapore (NUS) has successfully...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Mobile App Data Collection Shows Promise for Population Health Surveys
News | Population Health | January 10, 2019
Mobile app data collection can bring access to more potential clinical study participants, reduce clinical study...
Hypertension With Progressive Cerebral Small Vessel Disease Increases Cognitive Impairment Risk
News | Magnetic Resonance Imaging (MRI) | January 08, 2019
Patients with high blood pressure and progression of periventricular white matter hyperintensities showed signs of...
Artificial Intelligence Pinpoints Nine Different Abnormalities in Head Scans

A brain scan (left) showing an intraparenchymal hemorrhage in left frontal region and a scan (right) of a subarachnoid hemorrhage in the left parietal region. Both conditions were accurately detected by the tool. Image courtesy of Nature Medicine.

News | Artificial Intelligence | January 07, 2019
The rise in the use of computed tomography (CT) scans in U.S. emergency rooms has been a well-documented trend1 in...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...